The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Novel Antiangiogenic Mechanisms


Clinical Science Symposium
Chair(s): Janet Dancey, MD
Developmental Therapeutics Track
2008 ASCO Annual Meeting


Sort by: presentation order title speaker
Search Virtual Meeting

PRESENTATON TITLE SPEAKER/ROLE Basic Player Enhanced Player
Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study.

Abstract No: 5007
Roberto Pili, MD
Presenter
Video & Slides Play
Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer.

Abstract No: 3504
Jason Lickliter, MBBS, FRACP
Presenter
Video & Slides Play
Discussion
Robert S. Kerbel, PhD
Discussant
Video & Slides Play
Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases.

Abstract No: 3506
Suso Platero, PhD
Presenter
Video & Slides Play
Discussion
Anton Wellstein, MD, PhD
Discussant
Video & Slides Play




This online resource is supported by:
Primary Supporter  


 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.